TINAGL1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue, Primary antibody: P09164(TINAGL1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P09164(TINAGL1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

**Background of TINAGL1 Antibody**

TINAGL1 (Tubulointerstitial Nephritis Antigen-Like 1), also known as lipocalin 7. is a secreted glycoprotein encoded by the *TINAGL1* gene. It is structurally related to the tubulointerstitial nephritis antigen (TINAG) and shares homology with lipocalins, a family of proteins involved in lipid transport and cell signaling. TINAGL1 is ubiquitously expressed, with notable presence in the kidneys, liver, and reproductive tissues, and plays roles in extracellular matrix organization, cell adhesion, and modulation of signaling pathways, including EGFR and integrin-mediated pathways.

Research highlights TINAGL1's dual role in cancer biology, acting as either a tumor suppressor or promoter depending on context. It inhibits tumor progression in breast and lung cancers by suppressing metastasis-related pathways, yet promotes ovarian cancer growth via lipid metabolism regulation. Dysregulation of TINAGL1 is also implicated in kidney diseases, particularly tubulointerstitial nephritis, where it may serve as an autoantigen.

TINAGL1 antibodies are essential tools for detecting and quantifying the protein in research applications such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies aid in elucidating TINAGL1's tissue distribution, interaction networks, and mechanistic roles in diseases. Commercial antibodies are typically raised against specific epitopes, available as monoclonal or polyclonal forms, and validated for specificity across human and model organisms. Ongoing studies focus on TINAGL1's potential as a diagnostic biomarker or therapeutic target, particularly in cancers and renal pathologies.